纳米镜治疗公司宣布参加Eyecelerator®和ARVO 2025年度会议-动脉网

Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2025 Annual Meetings

CISION 等信源发布 2025-04-26 04:19



可切换为仅中文







Presentations to highlight efficacy, durability, and safety of Nanoscope's optogenetic therapy platforms

展示纳米镜公司光遗传治疗平台的有效性、持久性和安全性的演讲

DALLAS

达拉斯

，

April 25, 2025

2025年4月25日

/PRNewswire/ --

Nanoscope Therapeutics Inc.

纳米镜治疗公司

, a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced participation at both the

，一家致力于通过开发和商业化针对视网膜退行性疾病的新型基因疗法，在现实环境中为盲人患者恢复视力的生物技术公司，今天宣布将参与两项活动：

Eyecelerator

眼加速器

and

和

The Association for Research and Vision in Ophthalmology (ARVO) 2025

2025年眼科研究与视觉协会（ARVO）

annual meetings. Nanoscope's presentations will be centered around 126-week outcomes following treatment with its

年度会议。Nanoscope的报告将围绕其治疗后126周的成果展开。

MCO-010 optogenetic therapy

MCO-010 光遗传学疗法

for retinitis pigmentosa (RP), the first and only therapy

针对视网膜色素变性（RP）的首个也是唯一的疗法

shown to restore vision in advanced RP patients

证明可以恢复晚期RP患者的视力

via a one-time, standard intravitreal injection.

通过一次性、标准的玻璃体内注射。

'We are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and look forward to sharing more about the positive therapeutic benefits seen in RP patients treated with our multi-characteristic opsin, or MCO, therapy,' said Dr.

“我们很高兴在Eyecelerator和ARVO年会上有如此重要的参与，并期待分享更多关于RP患者接受我们多特征视蛋白（MCO）治疗后所带来的积极疗效的信息，”博士表示。

Samarendra Mohanty

萨曼德拉·莫汉蒂

, co-founder and President of Nanoscope. 'Multi-year benefit is meaningful for patients looking for a one-time, durable treatment option for their irreversible, progressive vision loss due to RP, and it underscores the potential of MCO-010 to redefine the standard of care. It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, including BLA submission.'.

“, Nanoscope的联合创始人兼总裁。‘对于那些因视网膜色素变性（RP）而导致不可逆、进行性视力丧失的患者来说，多年的益处意味着一种一次性、持久的治疗选择，这突显了MCO-010重新定义护理标准的潜力。在Nanoscope，当我们准备将MCO-010商业化，包括提交生物制品许可申请（BLA）时，这是一个激动人心的时刻。’”

Details of the presentations are as follows:

演示文稿的详细信息如下：

Eyecelerator | Ophthalmic Innovation Conference

眼科加速器 | 眼科创新会议

Friday, May 2

5月2日，星期五

, 2025

，2025

Grand

宏伟的

Hyatt Deer Valley

凯悦鹿谷

，

Park City, UT

犹他州帕克城

Nanoscope participation:

纳米镜参与：

12:30 – 1:30pm MDT

– Panel – I Shall be Released: Novel Drug Delivery Approaches for Glaucoma and Retina – Dr.

－面板－我将被释放：青光眼和视网膜的新型药物递送方法－博士

Sam Barone

萨姆·巴罗内

, Chief Medical Officer

，首席医疗官

1:59 – 2:04pm MDT; Strawberry Ballroom

下午1:59 – 2:04 MDT；草莓舞厅

– Presenting Company Showcases: Retina: Gene Therapy and Novel Mechanisms of Action – Dr.

- 公司展示：视网膜：基因治疗和新颖的作用机制 - 博士

Jared Stephens

贾里德·斯蒂芬斯

, Vice President, Strategy and Business Development

，副总裁，战略与业务发展

3:30 –

3点30分 –

4:15pm

下午4点15分

MDT

– Panel – No Direction Home: Guidance for Navigating Increasingly Complex Regulatory Pathways – Dr.

– 面板 – 无方向之家：驾驭日益复杂的监管路径的指导 – 博士

Sam Barone

萨姆·巴罗内

ARVO, The Association for Research in Vision and Ophthalmology

ARVO，视觉与眼科研究协会

Sunday, May 4

5月4日，星期日

泰国

到

Thursday, May 8

5月8日，星期四

第

, 2025

，2025

Salt Palace Convention Center,

盐宫会议中心，

Salt Lake City, UT

犹他州盐湖城

Nanoscope presentations:

纳米镜演示：

Sunday, May 4

5月4日，星期日

, 1:30 –

，1:30 –

1:45pm MDT

下午1点45分（MDT）

; Ballroom G

；舞厅 G

– Ms.

– 女士

Lucero Garcia

卢塞罗·加西亚

presenting – 'Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in NHP model of geographic atrophy'

呈现——“多特性视蛋白基因疗法减轻视网膜退化并恢复地理性萎缩NHP模型的视力”

Tuesday, May 6

5月6日，星期二

, 9:15 –

，9:15 –

9:30am MDT

上午9点30分（MDT）

; Ballroom B

；舞厅 B

– Dr. SriniVas Sadda presenting – '126-Week Visual Acuity Outcomes Following Mutation-Agnostic Optogenetic Therapy, MCO-010, for Retinitis Pigmentosa (RP)'

– SriniVas Sadda 博士展示 – “针对视网膜色素变性（RP）的非基因突变依赖性光遗传学疗法 MCO-010 的 126 周视力结果”

Thursday, May 8

5月8日，星期四

, 2:45 –

，2:45 –

3:00pm MDT

下午3点（山区夏令时）

; Ballroom F

；舞厅 F

– Dr.

博士

Naj Sharif

纳吉·沙里夫

presenting – 'Safety and Efficacy of an Image-Guided Laser-based Non-Viral Targeted Delivery of Multi-Characteristic Opsin Plasmids in African Green Monkey Retinae'

呈现——“基于图像引导的激光非病毒靶向递送多特征视蛋白质粒在非洲绿猴视网膜中的安全性和有效性”

Nanoscope team members will be available at Booth 1337 for the duration of the ARVO conference.

纳米镜团队成员将在ARVO会议期间全程在1337号展位提供服务。

About Nanoscope Therapeutics Inc.

关于Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (.

纳米镜治疗公司正在开发与基因突变无关的、恢复视力的光遗传学疗法，针对数百万因视网膜退行性疾病而失明的患者，目前尚无治疗方法。在RESTORE第二阶段多中心、随机、双盲、假对照临床试验中获得了积极的最终研究结果。

NCT04945772

), the company announced its plan to initiate a

），该公司宣布了其启动计划

BLA submission for MCO-010 to treat RP

MCO-010治疗RP的BLA提交

in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (

2025年上半年。该公司已经完成了MCO-010疗法在斯塔加特病患者中的二期STARLIGHT试验（

NCT05417126

) and plans to initiate a

）并计划启动一项

Phase 3 registrational trial

第三阶段注册试验

, also in 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

，同样在2025年。MCO-010已经获得了FDA的快速通道指定和FDA的孤儿药指定，适用于RP和Stargardt病。临床前项目包括一个IND就绪的非病毒激光递送MCO-020资产用于GA，以及一个用于Leber先天性黑蒙症的AAV资产，正在进行IND支持性研究。

Investor Contact:

投资者联系方式：

Argot Partners

行话伙伴

212-600-1902

PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

源纳米镜治疗公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?